Search results for: “keytruda”
-
Blog
What Cancer Patients Need to Know About the Opdivo Approval
Now that Opdivo (nivolumab) has been FDA approved for two cancer types, many patients are wondering: what’s…
-
Blog
Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer
The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung…
-
Blog
Immune Checkpoint Inhibitors: What’s Next?
What’s ahead beyond CTLA-4 and PD-1?
-
Blog
What’s in a Name?
Cancer immunotherapies can have some mind-boggling names. But there’s a reason for it all.
-
Blog
CRI’s 2014 Blog in Review: Top 10
We reflect on our favorite blog posts of 2014, including FDA approvals, editorials, conference coverage, history, awards,…
-
Blog
New Cancer Immunotherapy Opdivo Approved by FDA
Just hours ago, the FDA approved Bristol-Myers Squibb's PD-1 drug for melanoma.
-
Blog
Breaking Through: 2014 Annual Report Highlights
Discover why this past year was one of many breakthroughs for the Cancer Research Institute with our…
-
Blog
Immunotherapy for Blood Cancers: What to Look for at the Upcoming ASH Meeting
Look for the latest results from trials of PD-1 inhibitors and new developments in adoptive cell transfer.
-
Blog
FDA Approves New Cancer Immunotherapy
Merck's new immunotherapy, Keytruda (pembrolizumab), was approved today by the FDA, making it the first PD-1 inhibitor…